Self-assessment of the oral cavity by patients during radio(chemo)therapy for head-and-neck tumours

2007 ◽  
Vol 82 ◽  
pp. S85
Author(s):  
W. Dörr ◽  
E. Dörr ◽  
T. Herrmann
Keyword(s):  
Oral Cavity ◽  
Head And Neck ◽  
Head And Neck Tumours ◽  
Self Assessment

scholarly journals “AGGRESSIVE” CLEAR CELL CHONDROSARCOMA OF THE HARD PALATE

2017 ◽  
Vol 10 (5) ◽  
pp. 78
Author(s):  
Ajay M Bhandarkar ◽  
Balakrishnan Ramaswamy
Keyword(s):  
Soft Tissue ◽  
Oral Cavity ◽  
Head And Neck ◽  
Hard Palate ◽  
Clear Cell ◽  
Histopathological Analysis ◽  
Head And Neck Tumours ◽  
Clear Cell Chondrosarcoma ◽  
One Year

Chondrosarcomas constitute 1 to 3% of all head and neck tumours. 2% of all chondrosarcomas are of the “clear cell” variety which follow a locally aggressive, relatively indolent course without predominant invasion of soft tissue. We present a 45-year-old woman presented with a bleeding mass in the oral cavity with change of voice of one year duration with pain of one month duration and histopathological analysis revealed a clear cell chondrosarcoma.

scholarly journals Oral and Maxillo-Facial Manifestations of Systemic Diseases: An Overview

Medicina ◽  
2021 ◽  
Vol 57 (3) ◽  
pp. 271
Author(s):  
Saverio Capodiferro ◽  
Luisa Limongelli ◽  
Gianfranco Favia
Keyword(s):  
Early Diagnosis ◽  
Oral Cavity ◽  
Head And Neck ◽  
Clinical Outcomes ◽  
Systemic Disease ◽  
Clinical Manifestations ◽  
Systemic Diseases ◽  
Special Issue ◽  
Hard Tissues ◽  
Current Special Issue

Many systemic (infective, genetic, autoimmune, neoplastic) diseases may involve the oral cavity and, more generally, the soft and hard tissues of the head and neck as primary or secondary localization. Primary onset in the oral cavity of both pediatric and adult diseases usually represents a true challenge for clinicians; their precocious detection is often difficult and requires a wide knowledge but surely results in the early diagnosis and therapy onset with an overall better prognosis and clinical outcomes. In the current paper, as for the topic of the current Special Issue, the authors present an overview on the most frequent clinical manifestations at the oral and maxillo-facial district of systemic disease.

scholarly journals Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model

2021 ◽  
Vol 13 ◽  
pp. 175883592098406
Author(s):  
Vanesa Gutiérrez Calderón ◽  
Alexandra Cantero González ◽  
Laura Gálvez Carvajal ◽  
Yolanda Aguilar Lizarralde ◽  
Antonio Rueda Domínguez
Keyword(s):  
Squamous Cell Carcinoma ◽  
Oral Cavity ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Surgical Resection ◽  
Squamous Cell ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Research Model

Squamous cell carcinoma of oral cavity (OCSCC) accounts for approximately 25% of cases of head and neck squamous cell carcinoma (HNSCC). Tobacco and alcohol consumption are the main risk factors for both cancers. Surgical resection, combined with adjuvant radiotherapy or radiochemotherapy in patients with high risk of relapse, is the key element in management in the initial stages. However, despite the availability of aggressive multidisciplinary treatments, advanced resectable OCSCC carries poor prognosis; only half of the patients are disease-free 5 years after the surgery. Immunotherapy based on the use of immune checkpoint inhibitors has been proven to be effective in a wide variety of tumours, including recurrent and metastatic HNSCC. These positive results resulted in investigations into its effectiveness in earlier stages of the disease with OCSCC emerging as an interesting research model because of the accessible location of the tumours. This article reviews the potential advantages of emerging immunotherapeutic agents [mainly monoclonal antibodies against programmed cell death-1 ( PD-1) immune checkpoint inhibitors] as neoadjuvant treatment for OCSCC at locoregional stages as well as the ongoing clinical trials, challenges in evaluating tumour response, and possible predictive biomarkers of response with highlights regarding the role of oral microbiota as modulators of immune response. The efficacy and safety of anti- PD-1 drugs in these patients have been proven in preliminary trials. If there is a decrease in the relapse rate and an improvement in the overall survival after surgical resection in ongoing trials, preoperative immunotherapy may be established as a treatment option for patients with early stages of the disease.

Human Papillomavirus in Various Lesions of the Head and Neck

1985 ◽  
Vol 93 (3) ◽  
pp. 342-346 ◽  
Author(s):  
Melvin Strauss ◽  
A. Bennett Jenson
Keyword(s):  
Human Papillomavirus ◽  
Oral Cavity ◽  
Head And Neck ◽  
Adult Onset ◽  
Childhood Onset ◽  
Oncogenic Potential ◽  
Suggestive Evidence ◽  
Malignant Lesions ◽  
Epithelial Lesions

The association of human papillomavirus with benign and malignant epithelial lesions of the head and neck has been studied by a peroxidase-antiperoxidase technique having immunospecificity against genus-specific structural antigens of the papillomaviruses. More than 360 specimen blocks from 144 patients were evaluated. There was evidence of human papillomavirus antigen in three out of eight patients with childhood-onset laryngeal papillomas (37.5%) and in four out of eight patients with adult-onset papillomas (50%). A patient with an unusual flat, wartlike lesion appearing as an oral cavity leukoplakia had detectable papillomavirus antigen in it. None of the 13 cases of inverting papilloma or any of the malignant lesions studied showed evidence for the presence of papillomavirus antigen. There is currently only suggestive evidence for the oncogenic potential of human papillomavirus in the head and neck.

Sign in / Sign up

Export Citation Format

Share Document